Preferred Label : riociguat;

MeSH note : structure in first source;

CISMeF synonym : BAY 63-2521;

MeSH hyponym : BAY-63-2521;

MeSH Related Number : 625115-55-1;

Registry Number MeSH : 625115-55-1;

Is substance : O;

UNII : RU3FE2Y4XI;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3500927/fr/adempas-riociguat-hypertension-arterielle-pulmonaire-htap
2024
France
evaluation of the transparency committee
riociguat
riociguat
Pulmonary Arterial Hypertension
Adempas
Pulmonary Arterial Hypertension
pulmonary hypertension, nos
hypertensive disease, nos
riociguat
Riociguat

---
https://www.has-sante.fr/jcms/p_3222368/fr/adempas
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
riociguat
hypertension, pulmonary
evaluation of the transparency committee
riociguat
pyrazoles
pyrimidines

---
https://www.has-sante.fr/jcms/p_3210936/fr/adempas
2020
false
false
false
France
riociguat
insurance, health, reimbursement
adult
hypertension, pulmonary
Chronic thromboembolic pulmonary hypertension
thromboembolism
evaluation of the transparency committee
riociguat
pyrazoles
pyrimidines

---
ADEMPAS (riociguat) - New Contraindication for Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias (PH-IIP)
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59816a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
hypertension, pulmonary
riociguat
riociguat
administration, oral
idiopathic interstitial pneumonias
Contraindications, Procedure
pyrazoles
pyrimidines
Contraindications, Drug

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64832942
2014
false
false
false
France
French
summary of product characteristics
seborrhea sicca
riociguat
riociguat
pill, nos
dandruff
tablets
riociguat
compression, nos
dandruff
pyrazoles
pyrimidines

---
https://www.ema.europa.eu/medicines/human/EPAR/Adempas
2014
false
United Kingdom
English
French
riociguat
riociguat
drug approval
europe
treatment outcome
guanylate cyclase
orphan drug production
summary of product characteristics
package leaflet
drug evaluation
syndication feed
hypertension, pulmonary
adult
motor activity
chronic disease
thromboembolism
administration, oral
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
clinical trials, phase iii as topic
drug evaluation, preclinical
pyrazoles
pyrazoles
pyrimidines
pyrimidines
Chronic thromboembolic pulmonary hypertension
riociguat

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=66086562
2014
false
false
false
France
French
summary of product characteristics
tablets
riociguat
seborrhea sicca
riociguat
compression, nos
riociguat
dandruff
pill, nos
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60025054
2014
false
false
false
France
French
summary of product characteristics
seborrhea sicca
riociguat
riociguat
pill, nos
dandruff
riociguat
compression, nos
tablets
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60203795
2014
false
false
false
France
French
summary of product characteristics
dandruff
riociguat
compression, nos
seborrhea sicca
riociguat
riociguat
tablets
pill, nos
dandruff
pyrazoles
pyrimidines

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61875550
2014
false
false
false
France
French
summary of product characteristics
pill, nos
dandruff
tablets
riociguat
compression, nos
seborrhea sicca
riociguat
riociguat
dandruff
pyrazoles
pyrimidines

---
http://www.has-sante.fr/portail/jcms/c_1761611/fr/adempas
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
riociguat
hypertension, pulmonary
adult
drug therapy, combination
treatment outcome
Chronic thromboembolic pulmonary hypertension
orphan drug production
riociguat
guidelines for drug use
riociguat
pyrazoles
pyrimidines
pyrazoles
pyrimidines

---
Summary Basis of Decision (SBD) for Adempas
Riociguat, 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg, tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00171
2013
false
Canada
English
French
drug approval
canada
riociguat
riociguat
administration, oral
tablets
hypertension, pulmonary
chronic disease
adult
guanylate cyclase
recurrence
treatment outcome
pulmonary embolism
clinical trials as topic
drug evaluation
rare diseases
pyrazoles
pyrazoles
pyrimidines
pyrimidines
riociguat
drug information
Product containing riociguat in oral dose form (medicinal product form)
Chronic thromboembolic pulmonary hypertension

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.